Retrospective Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Apr 7, 2016; 22(13): 3632-3643
Published online Apr 7, 2016. doi: 10.3748/wjg.v22.i13.3632
Figure 1
Figure 1 Overall survival periods significantly increase in the transcatheter arterial chemoembolisation group compared with the other groups. 1Group 1: TACE administration; Group 2: Surgery + postoperative TACE; Group 3: Monotherapy of sorafenib; Group 4: Palliative therapy.